Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $2.77, $0.02 better than the analyst estimate of $2.75. Revenue for the quarter came in at $973.1 million versus the consensus estimate of $997.96 million.

GUIDANCE:

Charles River Laboratories sees FY2022 EPS of $10.70-$10.95, versus the consensus of $11.53. Sees revenue up 9-11% versus prior of 13.5-15.5%.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.